Artivion (NYSE:AORT) SVP Sells $38,847.86 in Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 1,493 shares of Artivion stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $26.02, for a total value of $38,847.86. Following the sale, the senior vice president owned 51,640 shares of the company’s stock, valued at approximately $1,343,672.80. This trade represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Artivion Stock Up 0.1%

Shares of AORT opened at $25.59 on Monday. The firm has a fifty day moving average price of $26.09 and a 200-day moving average price of $29.16. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.25 billion, a P/E ratio of -365.52 and a beta of 1.25. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The company had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. Equities research analysts expect that Artivion, Inc. will post 0.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research report on Monday, June 1st. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Finally, Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.83.

Hedge Funds Weigh In On Artivion

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its holdings in Artivion by 73.1% during the first quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock valued at $3,430,000 after buying an additional 39,553 shares during the period. Orbimed Advisors LLC purchased a new stake in Artivion during the first quarter worth $5,530,000. Vanguard Group Inc. boosted its position in Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after acquiring an additional 141,030 shares in the last quarter. Summit Creek Advisors LLC bought a new stake in Artivion during the 2nd quarter valued at $2,704,000. Finally, UBS Group AG increased its holdings in shares of Artivion by 37.0% in the 4th quarter. UBS Group AG now owns 279,675 shares of the company’s stock valued at $12,756,000 after acquiring an additional 75,606 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.